TABLE 4.
Co‐delivery of TAM‐specific agents and chemotherapeutics/immune checkpoint inhibitors in BC
| Ligands/ Receptors | Therapeutic agents | Delivery systems | Therapeutic strategies targeting TAM | Tumor cell lines | References |
|---|---|---|---|---|---|
| Mannose/ CD206 | DOX | DOX‐AS‐M‐PLGA‐NPs | Depletion | M‐Wnt | 177 |
| DOX | PEI‐FCD‐DOX NPs | Reprogramming | 4T1 | 178 | |
| DOX | PEG‐PEI‐ZYM‐DOX NPs | Reprogramming | 4T1 | 179 | |
| HA/ CD44 | DOX | Fe3O4–DOX–HA | Reprogramming | 4T1 | 180 |
| ATpep / europilin‐1 + Fc receptor | DTX | ATpep‐NPs‐DTX | Phagocytosis | 4T1 | 181 |
| iRGD + ApoE / integrin + LDLR | MMC + DOX | iRGD‐DMTPLN | Depletion | MDA‐MB‐231 | 182 |
| Indoximod + DOX | DOX/IND@NPs | Depletion | 4T1 | 164 | |
| HCQ + DOX | AuNPs‐D&H‐R&C | Reprogramming | MCF‐7/ADR | 187 | |
| Chondroitin sulfate/ CD44 | Imiquimod + DOX | PLGA | Reprogramming | 4T1 | 184 |
| FA/ Folate receptor | DHA + PTX | PTX/DHA‐FA‐LNs | Reprogramming | MCF7 | 185 |
| aCD47 + PTX | PTX‐Ilips | Phagocytosis | MDA‐MB‐231 | 186 | |
| Pexidartinib + aPD‐1 antibody | PLX‐NP‐P‐aPD‐1@Gel | Depletion | 4T1 | 188 | |
| Pt(IV)+ CQ + DPPA‐1 | Pt(IV)/CQ/PFH NPs‐DPPA‐1 | Reprogramming | 4T1 | 189 |